INFLUENZA CVD 15000: EVALUATION OF A BOOSTER DOSE OF A/VIETNAM/1203/04 (H5N1)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 志愿者之前参与了一项研究，以测试一种针对A/H5N1禽流感病毒的实验性疫苗，现在他们被问及是否愿意参加一项扩展研究。作为最初研究的一部分，他们接种了两剂A/H5N1禽流感疫苗。在新的研究中，志愿者将接受第三剂(加强剂)，剂量水平与最初的研究相同。疫苗由赛诺菲巴斯德公司(以前称为安万特巴斯德公司)制造，其制作方法与常规流感疫苗相同。甲型H5N1禽流感疫苗尚未获得美国食品和药物管理局的批准在美国使用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Volunteers previously took part in a research study to test an experimental vaccine against the A/H5N1 bird flu virus and are now being asked if they would like to take part in an extension study. As part of the original study, they received two doses of the A/H5N1 bird flu vaccine.In the new study volunteers will receive a third dose (booster) at the same dose level as the original study.The vaccine, which is made by sanofi pasteur, Inc. (previously known as Aventis Pasteur, Inc.), is made the same way that the "regular flu" vaccine is made. The A/H5N1 bird flu vaccine is not yet approved by the Food and Drug Administration for use in the United States.